Leishmanin skin test lymphoproliferative responses and cytokine production after symptomatic or asymptomatic Leishmania major infection in Tunisia

Clinical and Experimental Immunology

Volumn 116, Issue 1, 1999, Pages 127-132

  Sassi, A ^c   Louzir, H ^a   Salah, A Ben ^a   Mokni, M ^b   Osman, A Ben ^b   Dellagi, K ^c  

^a PASTEUR INSTITUTE OF TUNIS   (Tunisia)

^b LA RABTA HOSPITAL   (Tunisia)

^c Pasteur Institute of Tunis ^*

Author keywords

Cytokines; Human; Leishmaniasis; Skin test; T cells

Indexed keywords

CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 4;

ADOLESCENT; ADULT; ARTICLE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; HUMAN; LEISHMANIA MAJOR; LYMPHOCYTE PROLIFERATION; PRIORITY JOURNAL; SKIN LEISHMANIASIS; SKIN TEST; TUNISIA;

ADOLESCENT; ADULT; ANIMALS; ANTIGENS, PROTOZOAN; CHILD; CYTOKINES; HUMANS; HYPERSENSITIVITY, DELAYED; INTERFERON TYPE II; INTERLEUKIN-10; INTERLEUKIN-4; LEISHMANIASIS, CUTANEOUS; LYMPHOCYTE ACTIVATION; MIDDLE AGED; SKIN TESTS; T-LYMPHOCYTES; TUNISIA;

EID: 0032933716     PISSN: 00099104     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2249.1999.00844.x     Document Type: Article

References (33)

1. 1 WHO Expert Committee. Control of the leishmaniasis. WHO Tech Rep Ser 1990; 793:1-158.
2. 2 Ben Ismail R, Gradoni L, Gramiccia M, Bettini S, Ben Rachid MS. Epidemic cutaneous leishmaniasis in Tunisia. Biochemical characterization of parasites. Trans R Soc Trop Med Hyg 1986; 80:669-70.
3. 3 Ben Salah A, Zakraoui H, Zatour A et al. A randomized placebo-controlled trial in Tunisia of treating cutaneous leishmaniasis with paramomycin ointment. Am J Trop Med Hyg 1995; 53:162-6.
4. 4 Manson-Bahr PEC. Diagnosis. In: Peters W, Killick-Kendrick R, eds. The Leishmaniasis in biology and medicine. London: Academic Press, 1987:703-29.
5. 5 Alvarado R, Enk C, Jaber K, Schur L, Frankenburg S. Delayed-type hypersensitivity and lymphocyte proliferation in response to Leishmania major infection in group of children in Jericho. Trans Roy Soc Trop Med Hyg 1989; 83:189-92.
6. 6 Weigle KA, Valderama L, Arias AL et al. Leishmanin skin test standardization and evaluation of safety, dose, storage, longevity of reaction, and sensitization. Am J Trop Med Hyg 1991; 44:260-71.
7. 7 Weigle KA, Valderama L, Arias AL et al. Epidemiology of cutaneous leishmaniasis in Colombia: a longitudinal study of the natural history, prevalence, and incidence of infection and clinical manifestations. J Infect Dis 1993; 168:699-708.
8. 8 Guirges SY. Natural and experimental re-infection of man with Oriental sore. Ann Trop Med Parasitol 1971; 65:197-205.
9. 9 Davies CR, Llanos-Cuentas EA, Pyke SDM et al. Cutaneous Leishmaniasis in the Peruvian Andes: an epidemiological study of infection and immunity. Epidemiol Infect 1995; 114:297-318.
10. 10 Reiner SL, Locksley RM. The regulation of immunity to Leishmania major. Annu Rev Immunol 1995; 13:151-77.
11. 11 Passwell JH, Shor R, Tran H, Sholiam J, Jaffe C. Antigen-stimulated lymphokines from patients with cutaneous leishmaniasis induce monocyte killing of Leishmania major cellular amastigotes. J Immunol 1987; 139:4208-12.
12. 12 Murray HW, Rubin BY, Rothermel CD. Killing of intracellular Leishmania donovani by lymphokine-stimulated human mononuclear phagocytes. Evidence that interferon-gamma is the activating lymphokine. J Clin Invest 1983; 72:1506-12.
13. 13 Reed SG, Scott P. T-cell and cytokine responses in leishmaniasis. Curr Opin Immunol 1993; 5:524-31.
14. 14 Carvalho EM, Johnson WD, Barreto E et al. Cell mediated immunity in American cutaneous and mucosal leishmaniasis. J Immunol 1985; 135:4144-8.
15. 15 Melby PC, Neva FA, Sacks DL. Profile of human T cell response to leishmanial antigens: analysis by immunoblotting. J Clin Invest 1989; 83:1868-75.
16. 16 Pirmez C, Cooper C, Paes-Oliveira M, Schubach A, Torigian VK, Modlin RL. Immunologic responsiveness in American cutaneous leishmaniasis lesions. J Immunol 1990; 145:3100-4.
17. 17 Kemp M, Hey AS, Kurtzhals AL et al. Dichotomy of the human T cell response to Leishmania antigens. I. Th1-like activity response to Leishmania major promastigote antigens in individuals recovered from cutaneous leishmaniasis. Clin Exp Immunol 1994; 96:410-5.
18. 18 Rafati S, Couty-Jouve S, Alimhammadian MH et al. Biochemical analysis and immunogenicity of Leishmania major amastigote fractions in cutaneous leishmaniasis. Clin Exp Immunol 1997; 110:203-11.
19. 19 Louzir H, Melby PC, Ben Salah A et al. Immunologic determinants of disease evolution in localized cutaneous leishmaniasis due to Leishmania major. J Infect Dis 1998; 177:1687-95.
20. 20 Sokal JE. Measurement of delayed skin test responses. N Engl J Med 1975; 293:501-2.
21. 21 Scott P, Pearce E, Natovitz P, Sher A. Vaccination against cutaneous leishmaniasis in murine model II. Immunological properties of protective and non protective subfractions of a soluble promastigotes extract. J Immunol 1987; 139:3118-25.
22. 22 Badaro R, Jones TC, Lorenço R et al. A prospective study of visceral leishmaniasis in an endemic area of Brazil. J Infect Dis 1986; 154:639-49.
23. 23 Zijlstra EE, El-Hassen AM. Leishmanin and tuberculin sensitivity in leishmaniasis in the Sudan, with special reference to Kala-azar. Trans R Soc Trop Med Hyg 1993; 87:425-7.
24. 24 Many P, Lelievre A, Quaranta J-F, Rahal A, Gari-Toussaint M, Le Fichoux Y. Use of the leishmanin skin test and western blot analysis for epidemiological studies in visceral leishmaniasis areas: experience in a highly endemic focus in Alpes-Maritimes (France). Trans R Soc Trop Med Hyg 1994; 88:658-9.
25. 25 Kadaro AY, Ghalib HW, Ali MS et at. Prevalence of cutaneous leishmaniasis along the Nile river north of Khartoum (Sudan) in the aftermath of an epidemic in 1985. Am J Trop Med Hyg 1993; 48:44-49.
26. 26 Jumaian N, Kamhawi SA, Halalsheh M, Abdel-Hafez SK. Short report: outbreak of cutaneous leishmaniasis in a non immune population of soldiers in Wadi Araba, Jordan. Am J Trop Med Hyg 1998; 58:160-2.
27. 27 Mosmann TR, Moore KW. The role of IL-10 in crossregulation of Th1 and Th2 responses. Immunol Today 1991; 12:A49-A54.
28. 28 De Waal Malefyt R, Abrams J, Bennett B, Figdor CG, de Vries JE. Interleukin 10 (IL-10) inhibits cytokine synthesis by human monocytes: an autoregulatory role of IL-10 by human monocytes. J Exp Med 1991; 174:1209-20.
29. 29 Florentine DF, Zlotnik A, Vieira P et al. IL-10 acts on antigen-presenting cell to inhibit cytokine production by Th1 cells. J Immunol 1991; 146:3444-51.
30. 30 Del Prete G, De Carli M, Almerigogna F, Guidizi MG, Biagiotti R, Romagnagni S. Human IL-10 is produced by both type 1 helper (Th1) and type 2 helper (Th2) T cell clones and inhibits their antigen-specific proliferation and cytokine production. J Immunol 1993; 150:353-60.
31. 31 Karp CL, El-Safi SH, Wynn TA et al. In vivo cytokine profiles in patients with Kala-azar: marked elevation of both IL-10 and IFN-γ. J Clin Invest 1993; 91:1644-8.
32. 32 Ghalib HW, Pitivezam MR, Skeiky YAW et al. Interleukin 10 production correlates with pathology in human Leishmania donovani infections. J Clin Invest 1993; 92:324-9.
33. 33 Melby PC, Andrade-Narvaez FJ, Damell BJ, Valencia-Pacheco G, Tryon VV, Palomo-Cetina A. Increased expression of proinflammatory cytokines in chronic lesions of humans cutaneous leishmaniasis. Infect Immun 1994; 62:837-42.